Drug application
ABACAVIR SULFATE AND LAMIVUDINE (ABACAVIR SULFATE, LAMIVUDINE)
Drugs@FDA ANDA 205412 · HETERO LABS LTD V
Key facts
| Drug name | ABACAVIR SULFATE AND LAMIVUDINE |
|---|---|
| Active ingredients | ABACAVIR SULFATE, LAMIVUDINE |
| Application type | ANDA |
| Application number | 205412 |
| Company | HETERO LABS LTD V |
| Dosage forms | TABLET, ORAL |
| Strength | EQ 600MG BASE;300MG |
| Marketing status | Prescription |
| TE codes | AB |
| Reference listed drug | No |
| Latest submission status date | Apr 16, 2025 |
At a glance
- 1–9 Submissions
- 1–9 Supplements
- None Label versions
- 1–9 Products
- 1–9 Therapeutic equivalents
- Yes FDA letters on file
- No FDA reviews on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: